Latest Tiziana Life Sciences News & Updates

See the latest news and media coverage for Tiziana. We track all announcements, press releases, and industry mentions in real time, all in one place.

Tiziana Life Sciences (Tiziana)

Clinical-stage biopharmaceutical company developing immunotherapies and targeted cancer therapies

tizianalifesciences.com

Headquarters: London, United Kingdom
Company type: Public company
Number of employees: 11–50
Industry: Pharmaceuticals

Last updated October 15

Latest news about Tiziana Life Sciences (Tiziana)

In short: Tiziana advanced intranasal foralumab trials in Alzheimer's, MS, ALS, and MSA while reporting wider losses.

Company announcements

January 16 Tiziana

Tiziana Life Sciences announces up to $17.6 million offering

It prices 6,400,000 shares at $1.25 with warrants, led by CEO and Chairman. Proceeds complete Phase 2 na-SPMS and MSA trials.

December 15, 2025 Tiziana

Tiziana Life Sciences withdraws proposed public offering

The company announces withdrawal of common shares offering due to market conditions. Issued from Boston on December 15, 2025.

July 11, 2024 Tiziana

Tiziana receives FDA clearance for expanded Alzheimer's use

The investigational nasal spray foralumab gets compassionate access approval. First patient dosing begins July 2024 for moderate disease treatment.

August 16, 2023 Tiziana

Tiziana receives FDA clearance to test Foralumab for Alzheimer's

The IND clears intranasal Foralumab testing. The therapy targets neuroinflammation in Alzheimer's disease patients.

Media coverage

October 15 The Globe and Mail

Tiziana Life Sciences Posts Wider Interim Loss as Intranasal Foralumab Program Advances

Detailed price information for Tiziana Life Sciences Ltd (TLSA-Q) from The Globe and Mail including charting and trades.

October 15 Kauppalehti

Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

December 2, 2025 MarketWatch

Tiziana Life Sciences Plans to Spin Out Asset as Separate Company

Tiziana Life Sciences said it's planning to develop an antibody that blocks a critical inflammatory pathway via a spinout into a separate publicly-traded company. The...

April 20, 2025 Seeking Alpha

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

Meaningful Fatigue score reduction seen in study is a critically important quality of life (QoL) measure for Multiple Sclerosis patients. All patients experienced stabilization of...

Never miss news about Tiziana

Track Tiziana and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Tiziana competitors & trending companies

Browse news for competitors to Tiziana and other trending companies.